Terry wrote:What does it mean for an SPMS'er? That it buys one 5 years of stability?
Loobie wrote:My wife's aunt is in the trial. She has had MS for over 30 years and she says she feels nothing, but her MS is 'dug in' pretty good. She says she feels no side fx, so that's good, but she doesn't feel anything improving either. Those of you who have heard me talk of her know that she has been in about the same shape for as long as I've known her. She's a little slower here lately, but she's also getting on in years. Everything I've read about it seems promising, but so did Tovaxin when I read about it and it isn't doing much for me seeing as how I just got upgraded from a 3 to a 4 today at my 5th shot EDSS evaluation. But I hear it's helping others.
If the BioMS is getting 'fast-tracked' there must be something to it, eh? I'm very slowly starting to have to come to grips that I am probably progressive so I will be keeping an eye on this one.
INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study.
Users browsing this forum: No registered users